Alnylam Pharmaceuticals
ALNY
#622
Rank
C$45.48 B
Marketcap
$352.65
Share price
2.75%
Change (1 day)
46.56%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : C$5.99 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are C$5.99 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31C$5.37 B6.87%
2022-12-31C$5.02 B29.11%
2021-12-31C$3.89 B27.72%
2020-12-31C$3.04 B144.04%
2019-12-31C$1.24 B236.11%
2018-12-31C$0.37 B29.48%
2017-12-31C$0.28 B-37.66%
2016-12-31C$0.46 B172.49%
2015-12-31C$0.16 B1.58%
2014-12-31C$0.16 B4.04%
2013-12-31C$0.15 B4.76%
2012-12-31C$0.15 B-8.48%
2011-12-31C$0.16 B-29.03%
2010-12-31C$0.23 B-26.41%
2009-12-31C$0.31 B-25.52%
2008-12-31C$0.42 B45.85%
2007-12-31C$0.29 B550.08%
2006-12-31C$45.21 M6.19%
2005-12-31C$42.57 M77.55%
2004-12-31C$23.97 M-70.13%
2003-12-31C$80.28 M144.89%
2002-12-31C$32.78 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
C$1.36 B-77.26%๐Ÿ‡บ๐Ÿ‡ธ USA
C$11.66 B 94.50%๐Ÿ‡บ๐Ÿ‡ธ USA
C$3.41 B-42.99%๐Ÿ‡บ๐Ÿ‡ธ USA
C$1.22 B-79.57%๐Ÿ‡บ๐Ÿ‡ธ USA
C$9.99 M-99.83%๐Ÿ‡บ๐Ÿ‡ธ USA
C$86.32 B 1,339.91%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
C$87.42 B 1,358.14%๐Ÿ‡ซ๐Ÿ‡ท France
C$50.82 B 747.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel